Novavax initiated phase 3 efficacy trial of COVID-19 vaccine in the UK
On Sept. 24, 2020, Novavax announced that it had initiated its first Phase 3 study to evaluate the…
Fourth large-scale COVID-19 vaccine trial began in the United States
On Sept. 23, 2020, a fourth Phase 3 clinical trial evaluating an investigational vaccine for coronavirus disease 2019…
Sinovacﾒs Coronavacﾙ, SARS-CoV-2 vaccine, inactivated, announced approval for phase I/II clinical trial in adolescents and children
On Sept. 23, 2020, Sinovac Biotech announced that the inactivated COVID-19 vaccine candidate developed by Sinovac Life Sciences,…
Johnson & Johnson initiated pivotal global phase 3 clinical trial of Janssen’s COVID-19 vaccine candidate
On Sept. 23, 2020, Johnson & Johnson announced the launch of its large-scale, pivotal, multi-country Phase 3 trial…
Sinovac commenced phase III clinical trials for COVID-19 vaccine candidate in Turkey
On Sept. 22, 2020, Sinovac Biotech announced that it had recently commenced phase III clinical trials for its…
Serum Institute initiated manufacturing of Codagenix’s intranasal live-attenuated COVID-19 vaccine candidate
On Sept. 22, 2020, Codagenix announced that the Serum Institute of India has begun manufacturing CDX-005, the company’s…
Sanofi and GSK signed agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine
On Sept. 22, 2020, Sanofi and GSK announced they had signed agreements with the Government of Canada for…
Sanofi and GSK confirmed agreement with European Union to supply up to 300 million doses of adjuvanted COVID-19 vaccine
On Sept. 18, 2020, Sanofi and GSK finalised and signed an advanced purchase agreement with the European Commission…
BioNTech acquired GMP manufacturing site to expand COVID-19 vaccine production
On Sept. 17, 2020, BioNTech announced an agreement with Novartis to acquire their GMP certified manufacturing facility in…
Atossa Therapeutics received second positive safety assessment in clinical study of AT-301 Coronavirus nasal spray
On Sept. 17, 2020, Atossa Therapeutics announced a positive interim safety assessment from the second cohort of healthy…
T cells take the lead in controlling SARS-CoV-2 and reducing COVID-19 disease severity
On Sept. 16, 2020, a study by researchers at La Jolla Institute for Immunology published in the Cell,…
Biotechnology | COVID-19 | Infectious Disease | Influenza | NIH | Vaccine
Vaxess Technologies to develop Coronavirus + Influenza Combo Patch Vaccine in Partnership with Medigen
On Sept. 15, 2020, Vaxess Technologies and Medigen Vaccine Biologics (MBV) announced a partnership to develop a combined…
Thermo Fisher Scientific further expanded laboratory plastics production to support COVID-19 testing, therapies and vaccines
On Sept. 15, 2020, Thermo Fisher Scientific announced it was investing more than $140 million to further expand…
Soligenix announced publication demonstrating thermostabilization of filovirus vaccine antigens
On Sept. 15, 2020, Soligenix announced publication of nonclinical results characterizing filovirus protein antigens (including for Ebola and…
Tonix Pharma enrolled first patient in COV-LOGIC study to assess antibody and T cell responses to SARS-CoV-2
On Sept. 15, 2020,Tonix Pharmaceuticals announced that the first patient was enrolled in the observational COV-LOGIC study (TNX-C001),…
Novavax announced COVID-19 vaccine manufacturing agreement with Serum Institute of India
On Sept. 15, 2020, Novavax announced an amendment to its existing agreement with Serum Institute of India which…
BioNTech received ﾀ375M in funding from German Federal Ministry to support COVID-19 vaccine program BNT162
On Sept. 15, 2020, BioNTech announced that had receive a grant of up to 375 million Euro from…
Flu may increase the spread of Covid-19
On Sept. 14, 2020, scientists at the Max Planck Institute for Infection Biology in Berlin and the Institut…
Valneva announced COVID-19 vaccine partnership with UK Government
On Sept. 14, 2020, Valneva announced a vaccine partnership with the UK government for its inactivated COVID-19 vaccine,…
Valneva and Dynavax announced commercial supply agreement for inactivated, adjuvanted COVID-19 vaccine
On Sept. 14, 2020, Dynavax Technologies announced a commercial partnership for the supply of Dynavax’s CpG 1018 adjuvant…
COVID-19 vaccine AZD1222 clinical trials resumed in the UK
On Sept. 12 2020, Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK…
MediciNova announced intranasal RS virus vaccine vuccessfully induced neutralizing antibodies against RS virus in mice
On Sept. 11, 2020, MediciNova announced development progress on its intranasal SARS-CoV-2 vaccine for COVID-19 utilizing BC-PIV, a…
iBio advanced COVID-19 LicKM-subunit vaccine candidate, IBIO-201
On Sept. 9, 2020, iBio announced that it had selected IBIO-201, its LicKMﾙ-ubunit vaccine, as its leading candidate…
Merck announced positive topline results from phase 3 adult studies evaluating investigational 15-valent pneumococcal conjugate vaccine
On Sept. 9, 2020, Merck announced announced that two Phase 3 studies evaluating the safety, tolerability and immunogenicity…
AstraZeneca Oxford SARS-CoV-2 vaccine, AZD1222, COVID-19 vaccine trials temporary paused
On Sept. 9, 2020, as part of the ongoing randomised, controlled clinical trials of the AstraZeneca Oxford coronavirus…
Sinovac reported preliminary phase I/II results of COVID-19 vaccine in elderly volunteers
On Sept. 9, 2020, Sinovac Biotech announced that the inactivated COVID-19 vaccine candidate developed by Sinovac Life Sciences…
The ACIP updated flu vaccine recommendations for 2020-2021
On Sept. 9, 2020, the American Academy of Family Physicians (AAFP) reviewed and agreed with the Advisory Committee…
Valneva announced IXIARO supply contract with the U.S. Government worth up to $166 million
On Sept. 9, 2020, Valneva announced the signing of a new contract, lasting up to three years, with…
Pfizer and BioNTech announced data from preclinical studies of mRNA-based vaccine candidate against COVID-19
On Sept. 9, 2020, Pfizer and BioNTech announced preliminary preclinical data in mouse and non-human primate models from…
Pfizer and BioNTech to potentially supply EU with 200 million doses of mRNA-based vaccine candidate against SARS-CoV-2
On Sept. 9, 2020, Pfizer and BioNTech announced that they had submitted an amended protocol to the FDA…